What to Know About Tysabri Monitoring for PML Risk
From General Health Information to Occupational Exposure Concerns
If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page explains how dose and treatment duration influence PML risk in California, building on a foundation of clinical research that has shaped current monitoring recommendations.
Tysabri and PML: Mechanism, Risk Factors, and Regulatory Oversight
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and its clinical presentation can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is confirmed through brain imaging and detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in conditions like multiple sclerosis but also impairs normal immune surveillance against JCV in the brain. Under these conditions, latent JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Three established risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, healthcare professionals must monitor patients for any new sign or symptom suggestive of PML, and Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The program requires that patients be evaluated three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinicians must determine every six months whether patients should continue on treatment and, if so, authorize treatment for another six months. They must also report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Legal Considerations: Statute of Limitations for Tysabri PML Claims in California
The adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. The boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions have been raised about whether patients and healthcare providers were adequately informed about the magnitude of risk, particularly in relation to the identified risk factors. The TOUCH program is designed to ensure that patients understand these risks and that monitoring occurs, but some affected patients have argued that the warnings were insufficient to prevent harm. For patients in California who have developed PML after Tysabri treatment, settlement-related considerations involve the statute of limitations. In California, the statute of limitations for personal injury claims generally is two years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. For claims involving latent harm such as PML, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused their PML. The timeline between exposure and documented harm is critical: PML can develop after months to years of Tysabri therapy, with risk increasing beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate the determination of when the statute of limitations begins to run. Settlements in Tysabri PML cases have been reached in the past, with amounts varying based on factors such as the severity of disability, medical expenses, lost income, and the strength of evidence regarding inadequate warnings. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to assess their individual circumstances and ensure compliance with California's procedural requirements.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in California?
In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. For PML, which can have a latency period, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused their PML. It is crucial to consult an attorney promptly to avoid missing the deadline.
What are the risk factors for developing PML while on Tysabri?
Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.